about
Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trialVariations in process and outcomes of diabetes care by socio-economic status in Salford, UKThe evolution of diabetes information systems.Evaluation of an electrochemical sensor for measuring blood ketones.The cost of implementing UK guidelines for the management of chronic kidney disease.Serum phosphate and mortality in patients with chronic kidney diseaseObtaining real-world evidence: the Salford Lung Study.Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibilityEducational outreach in diabetes to encourage practice nurses to use primary care hypertension and hyperlipidaemia guidelines (EDEN): a randomized controlled trial.The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma.Type 2 diabetes whole-genome association study in four populations: the DiaGen consortiumThe Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease.The languages of health in general practice electronic patient records: a Zipf's law analysis.Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung StudyImpaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes.Kidney disease management in UK primary care: guidelines, incentives and information technology.Using the Internet to access confidential patient records: a case study.Variation in dialysis patient mortality by Health Authority.Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.In-patient management of diabetes mellitus and patient satisfaction.Evaluation of a bedside blood ketone sensor: the effects of acidosis, hyperglycaemia and acetoacetate on sensor performance.The unrecognized prevalence of chronic kidney disease in diabetes.Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial.Effect of Roux-en-Y Bariatric Surgery on Lipoproteins, Insulin Resistance, and Systemic and Vascular Inflammation in Obesity and Diabetes.Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.Putting patients in control of data from electronic health records.Measuring differences in the provision of diabetes care.Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS).Bariatric surgery in women of childbearing age.Renal autoregulation is normal in newly diagnosed, normotensive, NIDDM patients.Factors associated with kidney disease progression and mortality in a referred CKD population.Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass.Chronic kidney disease management in the United Kingdom: NEOERICA project results.Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population.40th EASD Annual Meeting of the European Association for the Study of DiabetesEffectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung StudyTelemedicine to improve glycaemic control: 3-year results from the Pro-Active Call Centre Treatment Support (PACCTS) trialThe use of eGFR and ACR to predict decline in renal function in people with diabetes
P50
Q28189788-FB5E9475-9C59-4508-9E8D-8516B6827C9CQ28196247-1B301B28-38BE-412C-9AD4-90FD3DA6A25CQ30739049-EFECBA7E-7AF9-4A7E-8CD5-FC7520D3A692Q31396577-00D1922F-E78F-4F1C-9ED3-48327C188B1EQ33286782-E53BD9EE-70EB-47E1-8360-467B20ADED04Q34362715-0FBA0CB6-D7A8-4790-80A7-168203393026Q34608276-883006D1-8189-48C8-91CE-E30DF1B6031BQ35091052-6A329B45-7080-447D-8CF8-8E32AD9CAD38Q35779059-7B4A7AE3-7B05-4D5F-8422-04D1D36E3178Q35864591-22DFB4E8-3ADA-42D3-99D5-C90A929EAC62Q35946296-1CE0DA6B-00A9-4E9F-A9F8-CACFF49B12D4Q36023343-6A9243A1-C89F-4D4E-93E7-419DBE5B9D5FQ37621855-BF6EE6AF-B603-4F0A-AEB1-D77FA6CB88AFQ37696453-D884EDEA-FB14-4517-B5A9-37A668266C89Q37783432-5A7CC0B9-706F-4647-94F7-648E6AF9070EQ38318479-78A5BD7F-3737-4610-B656-33879D8DBD70Q38573466-074A3EB5-91F9-4F94-93D8-F1AC17DC6F98Q38631208-B75D248F-585E-4135-929F-855417F3D0FAQ39665298-9E532663-DCAB-4C2D-A9B4-A95AC509F246Q40048314-D9D6B602-FF24-4921-9AF8-E875ABAEB5D1Q44004495-CEACC48B-9052-47EA-BF4C-443847746BD1Q44946406-0FD92262-5297-4974-ADAC-4BAFFD1454CEQ44946567-315C64E1-2039-4E19-918F-CC681F4FAC5AQ45199362-3522D84F-C70E-4667-94B9-FEED1FC7060FQ47134287-A4E8C61D-964A-4753-A117-31A1BE780316Q47189580-B5EC6F75-6189-4905-9B58-427602CA2278Q47218093-1FFAE225-A9FB-4F49-AAD9-5A6AABAE9F19Q47576888-36469FAF-7D2D-4AD9-8C9A-2CDBE4CBEAAEQ47607188-901B05FF-C2A9-4A00-999F-AE92B2FD1B19Q48050311-7EF9A140-4AF0-4647-B90C-887EDB91AE76Q50860388-6B8CF9D7-6E8D-408E-9CF4-BCC96879884AQ50903237-5510BB81-C0B2-4517-AA6F-B84E68F76FE2Q51149493-4875DA0C-01EA-48BD-8ECD-BEA36844E124Q51548830-FA673975-F9C5-4B1A-983A-50CC57A03E0FQ51917078-EF36C20C-800B-441E-954B-DEB860D979DDQ51940766-851F8DA5-F2D9-401C-9E54-903EDA164768Q57249806-558C2B0D-7D12-4EE3-AB20-8961808D205EQ57458020-E6901A10-68AE-44D6-BB6E-0269105DBB2DQ58618911-C68DC1F4-4B52-451B-9466-C6A9080E5146Q58851916-9946F35B-D6F8-46C2-BF82-E5DB74482E1D
P50
description
Forscher
@de
chercheur
@fr
forsker
@nb
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
J. New
@ast
J. New
@nl
John New
@en
John New
@es
John New
@nb
type
label
J. New
@ast
J. New
@nl
John New
@en
John New
@es
John New
@nb
altLabel
J. New
@en
prefLabel
J. New
@ast
J. New
@nl
John New
@en
John New
@es
John New
@nb
P31
P496
0000-0003-4146-025X